Taysha Gene Therapies granted stock options to two new employees totaling 212,000 shares under its 2023 Inducement Plan.
Quiver AI Summary
Taysha Gene Therapies, Inc., a biotechnology company focused on gene therapies for central nervous system diseases, announced the granting of stock options to two new employees on December 3, 2025. A total of 212,000 options to purchase common stock at an exercise price of $4.49 were awarded under the Taysha 2023 Inducement Plan. These options have a 10-year term and will vest over four years, contingent on the employees' continued service. Taysha is dedicated to developing therapies for severe monogenic conditions, such as Rett syndrome, leveraging its expertise and proven AAV technology to bring innovative treatments to patients.
Potential Positives
- The granting of stock options to new employees indicates the company's commitment to attracting talent, which is crucial for growth and innovation in a competitive biotechnology sector.
- The options are tied to a long-term vesting schedule, promoting employee retention and aligning their interests with the long-term success of the company.
- Taysha's focus on severe monogenic diseases and the development of transformative gene therapies highlights its potential to address significant unmet medical needs, positioning the company as a leader in a niche market with high demand.
- The company's management team has proven experience in gene therapy development, which enhances investor confidence in their ability to execute on their clinical programs successfully.
Potential Negatives
- Granting stock options to new employees can raise concerns about potential dilution of existing shareholders' equity, particularly if the stock options vest over a long period.
- The size of the grant (212,000 shares) could suggest a significant investment in new hires, which may lead to questions about the company's financial stability and ability to support such commitments.
- Issuing stock options may indicate that the company is trying to attract talent in a competitive market, suggesting potential challenges in recruitment or retention of employees in the biotechnology sector.
FAQ
What recent stock options were granted by Taysha Gene Therapies?
Taysha Gene Therapies granted options to purchase 212,000 shares to two new employees as part of their employment compensation.
What is the exercise price for Taysha's stock options?
The exercise price for the stock options is $4.49, matching the closing price of Taysha's common stock on the grant date.
How long is the term for Taysha's stock options?
Each stock option has a term of 10 years from the grant date.
What is Taysha Gene Therapies' focus in biotechnology?
Taysha Gene Therapies focuses on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.
What is Taysha's lead clinical program aimed at?
Taysha's lead clinical program, TSHA-102, is aimed at developing a treatment for Rett syndrome, a rare neurodevelopmental disorder.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TSHA Insider Trading Activity
$TSHA insiders have traded $TSHA stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $TSHA stock by insiders over the last 6 months:
- SUKUMAR NAGENDRAN (President and Head of R&D) has made 0 purchases and 4 sales selling 627,226 shares for an estimated $2,504,509.
- KAMRAN ALAM (CHIEF FINANCIAL OFFICER) sold 54,491 shares for an estimated $155,299
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TSHA Hedge Fund Activity
We have seen 90 institutional investors add shares of $TSHA stock to their portfolio, and 75 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JEFFERIES FINANCIAL GROUP INC. removed 8,157,091 shares (-79.1%) from their portfolio in Q3 2025, for an estimated $26,673,687
- RTW INVESTMENTS, LP added 6,233,718 shares (+33.2%) to their portfolio in Q2 2025, for an estimated $14,399,888
- BARCLAYS PLC added 4,697,611 shares (+1042.8%) to their portfolio in Q3 2025, for an estimated $15,361,187
- OCTAGON CAPITAL ADVISORS LP removed 3,525,000 shares (-28.0%) from their portfolio in Q3 2025, for an estimated $11,526,750
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 3,217,449 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $10,521,058
- BLACKROCK, INC. added 3,061,086 shares (+23.0%) to their portfolio in Q3 2025, for an estimated $10,009,751
- MPM BIOIMPACT LLC removed 2,953,562 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,658,147
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TSHA Analyst Ratings
Wall Street analysts have issued reports on $TSHA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 11/05/2025
- Chardan Capital issued a "Buy" rating on 11/05/2025
- Raymond James issued a "Strong Buy" rating on 10/21/2025
- Needham issued a "Buy" rating on 10/17/2025
- Baird issued a "Outperform" rating on 10/02/2025
- B of A Securities issued a "Buy" rating on 07/11/2025
To track analyst ratings and price targets for $TSHA, check out Quiver Quantitative's $TSHA forecast page.
$TSHA Price Targets
Multiple analysts have issued price targets for $TSHA recently. We have seen 8 analysts offer price targets for $TSHA in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Silvan Tuerkcan from Citizens set a target price of $8.0 on 11/05/2025
- Geulah Livshits from Chardan Capital set a target price of $12.0 on 11/05/2025
- Christopher Raymond from Raymond James set a target price of $13.0 on 10/21/2025
- Gil Blum from Needham set a target price of $10.0 on 10/17/2025
- Jack Allen from Baird set a target price of $12.0 on 10/02/2025
- Whitney Ijem from Canaccord Genuity set a target price of $14.0 on 08/13/2025
- Yanan Zhu from Wells Fargo set a target price of $8.0 on 08/13/2025
Full Release
DALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on December 3, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 212,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $4.49 which is equal to the closing price of Taysha's common stock on the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
[email protected]
Media Contact:
Carolyn Hawley
Inizio Evoke
[email protected]
